|
Jan 31
|
|
—
|
WATCH
|
Chamath Palihapitiya
Host, All-In Podcast / CEO, Social Capital
|
Neuralink has expanded human clinical trials to 21 participants, showing improved signal quality, and is launching new trials for "VOICE" (speech restoration) and "Blindsight" (visual perception) with FDA Breakthrough Device designation. While Neuralink is private, its rapid progress and FDA Breakthrough designation highlight the immense potential and accelerating innovation within the broader neurotechnology and medical device sectors. This could lead to increased investor interest and R&D spending in companies developing BCI, neuro-stimulation, and other advanced medical implants. Watch the Neurotechnology / Medical Devices sector for potential opportunities. While direct investment in Neuralink is not possible, its success could create a halo effect for public companies in the space, or signal future M&A activity. Neuralink's technology is still nascent and highly experimental; regulatory approval processes are lengthy and stringent; the market for such advanced devices may be niche initially. |
Chamath Palihapitiya
Neuralink's 21 Telepathy Trials in 2 Years
|